top of page


We are focused on benefitting patients that have failed to respond to current treatments. We do this by choosing targets that are more highly expressed in tumors – compared with the relative low expression of immune checkpoint pathway receptors that are targeted by many current drugs.

Our Pipeline

We are developing novel dual targeting antibody drugs to treat cancer by reducing toxicity and allowing the body's immune system to fight against cancer more effectively.

What We Are Doing

Our Team

Reiner Laus, MD

CEO + Founder

Shiva Bhowmik, PhD

COO + Founder

H. Kim Lyerly, MD

CMO +  Founder

William Brady

Director of Biotherapeutics

At TRIO Pharmaceuticals, our extraordinary team of scientists and innovators is dedicated to pushing the boundaries of healthcare. With diverse expertise in antibody research, drug development, and medical innovation, we work collaboratively to redefine possibilities and improve patient outcomes. Get to know the driving force behind our groundbreaking work – a team committed to shaping the future of transformative healthcare solutions.

  • SAN DIEGO and SAN FRANCISCO, April 30, 2020 /PRNewswire/ - Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody™, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate™ (TDC™) and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, are pleased to announce a development collaboration agreement to evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.

  • April 30, 2020 ADC Review | Journal of Antibody-drug Conjugates - Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies is that drugs that work by different mechanisms may be more effective since they may decrease or slow the likelihood of resistance.

  • In March, the San Diego-based TRIO announced a $2.2 million seed round, led by local investors SeedFolio, NuFund Venture Group and Friedman BioVentures and also, from Purdue University’s endowment fund and Japan-based Newsight Tech Angels Inc.. The seed funding follows a $400,000 SBIR (Small Business Innovation Research) grant awarded to the company in September 2022.

  • WEST LAFAYETTE, Ind. – Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000 in TRIO Pharmaceuticals Inc., a cancer immunotherapeutics startup founded by a Purdue University biophysics and structural biology alumnus. The company’s antibody-based therapeutics strengthens the body’s defense, the immune system, to eradicate cancer.


  • We have developed a TRAILBody™ that specifically targets ovarian and endometrial cancers. We are developing drug candidates to be used as a first line treatment, as well as for tumors that that did not respond to standard chemotherapy.

    Our Approach:

    Ovarian and endometrial cancers have high fatality rates due to late-stage detection, and recurrence after standard chemotherapy. Current therapies struggle to treat these cancers because they create an environment that weakens the immune system’s ability to detect and attack them effectively.

    The Challenge:

  • TNBC tumors lack key hormone receptors, are particularly aggressive and resistant to many conventional therapies. Immunotherapies for TNBC have limited efficacy due to its complex and diverse nature, hindering the immune system's ability to recognize and combat the cancer effectively. NSCLC, the most common type of lung cancer, responds to immunotherapies due to its higher mutation rate, which makes it more detectable to the immune system. Significant improvement in response rates to conventional and immunotherapies is needed to address the continued high mortality cause by these cancers

    The Challenge:

    We have developed a TIE-ADC™ that specifically targets TNBC and NSCLC tumors. We are developing drug candidates to be used as a first line treatment as well as for tumors that did not respond to the standard of care treatments.

    Our Approach:

  • We have developed a TRAILBody™ that specifically targets AML and MDS. We are developing drug candidates to be used as a first line treatment, as well as a combination therapy for tumors that that did not respond to standard chemotherapy.

    Our Approach:

    Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are both serious blood cancers, with AML characterized by the rapid proliferation of abnormal white blood cells, and

    MDS marked by the production of poorly formed or dysfunctional blood cells. Patients often relapse quickly after standard chemotherapy, highlighting the need for more effective treatment options. Current therapies struggle to treat these cancers.

    The Challenge:

Our novel dual-targeting antibodies are TIE-ADC™ and TRAILBody™.


TIE-ADC™ or Tumor Immunity Enhancing ADC™ kills both cancer cells and immunosuppressor cells removing immunosuppression in tumor. TIE-ADC is the first ever drug to attack two tumor promoting mechanisms with one drug. This strategy aims to enhance anti- tumor immune response by removing immunosuppression in the tumor.


TRAILBody™ directly kills cancer cells by activating endogenous cell death while sparing normal cells. TRAILBody is >1000-fold more potent than drugs that have previously been achieved using this pathway. It is the first ever drug that can directly kill cancer cells without using conjugated toxins or engaging immune effector cells. This strategy aims to provide effective cancer treatment without toxicity.

Our Approach

Efficacy of current cancer drugs is limited by harming healthy cells, and inability to launch an effective immune attack as cancer cells cleverly suppress immune responses. TRIO addresses these issues by developing a solution that precisely kills cancer cells, overcomes tumor immunosuppression, and allows the body’s immune system to fight against cancer more effectively.

The Challenge

TRIO stands out with a precision-driven cancer treatment approach. Our dual-targeting antibodies, TIE-ADC™ and TRAILBody™, uniquely address challenges in cancer treatment by selectively killing cancer cells and overcoming tumor immunosuppression. Importantly, our strategy aims to eliminate treatment-related toxicity whilst simultaneously enhancing efficient tumor elimination. TRIO pioneers a new era in cancer care, combining innovation and precision to outsmart cancer and enhance patient well-being.

What Sets Us Apart

bottom of page